Literature DB >> 14585961

Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms.

Isabella Gazzoli1, Richard D Kolodner.   

Abstract

Defects in human DNA mismatch repair have been reported to underlie a variety of hereditary and sporadic cancer cases. We characterized the structure of the MSH6 promoter region to examine the mechanisms of transcriptional regulation of the MSH6 gene. The 5'-flanking region of the MSH6 gene was found to contain seven functional Sp1 transcription factor binding sites that each bind Sp1 and Sp3 and contribute to promoter activity. Transcription did not appear to require a TATA box and resulted in multiple start sites, including two major start sites and at least nine minor start sites. Three common polymorphisms were identified in the promoter region (-557 T-->G, -448 G-->A, and -159 C-->T): the latter two were always associated, and each of these functionally inactivated a different Sp1 site. The polymorphic allele -448 A -159 T was demonstrated to be a common Caucasian polymorphism found in 16% of Caucasians and resulted in a five-Sp1-site promoter that had 50% less promoter activity and was more sensitive to inactivation by DNA methylation than the more common seven Sp1 site promoter allele, which was only partially inactivated by DNA methylation. In cell lines, this five-Sp1-site polymorphism resulted in reduced MSH6 expression at both the mRNA and protein level. An additional 2% of Caucasians contained another polymorphism, -210 C-->T, which inactivated a single Sp1 site that also contributes to promoter activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585961      PMCID: PMC262342          DOI: 10.1128/MCB.23.22.7992-8007.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  73 in total

Review 1.  Transient transfection of Schneider cells in the study of transcription factors.

Authors:  G Suske
Journal:  Methods Mol Biol       Date:  2000

Review 2.  DNA mismatch repair and genetic instability.

Authors:  B D Harfe; S Jinks-Robertson
Journal:  Annu Rev Genet       Date:  2000       Impact factor: 16.830

3.  Sp1 and Sp3 transactivate the RET proto-oncogene promoter.

Authors:  S D Andrew; P J Delhanty; L M Mulligan; B G Robinson
Journal:  Gene       Date:  2000-10-03       Impact factor: 3.688

4.  Polymorphisms in a pseudogene highly homologous to PMS2.

Authors:  R B Chadwick; J E Meek; T W Prior; P Peltomaki; A de La Chapelle
Journal:  Hum Mutat       Date:  2000-12       Impact factor: 4.878

5.  An inhibitor domain in Sp3 regulates its glutamine-rich activation domains.

Authors:  J Dennig; M Beato; G Suske
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

6.  Infrequent frameshift mutations in the simple repeat sequences of hMLH3 in hereditary nonpolyposis colorectal cancers.

Authors:  Y Akiyama; H Nagasaki; T Nakajima; H Sakai; T Nomizu; Y Yuasa
Journal:  Jpn J Clin Oncol       Date:  2001-02       Impact factor: 3.019

7.  Novel dominant mutations in Saccharomyces cerevisiae MSH6.

Authors:  R Das Gupta; R D Kolodner
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

8.  Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers.

Authors:  S M Lipkin; V Wang; D L Stoler; G R Anderson; I Kirsch; D Hadley; H T Lynch; F S Collins
Journal:  Hum Mutat       Date:  2001-05       Impact factor: 4.878

9.  The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters.

Authors:  F Aslam; L Palumbo; L H Augenlicht; A Velcich
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

10.  Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents.

Authors:  A Bearzatto; M Szadkowski; P Macpherson; J Jiricny; P Karran
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

View more
  23 in total

1.  Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer.

Authors:  Tomomi Higashi; Satoru Kyo; Masaki Inoue; Hideji Tanii; Kiyofumi Saijoh
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

2.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Dual promoters control the cell-specific expression of the human cell death-inducing DFF45-like effector B gene.

Authors:  Liang Da; Dong Li; Kazunari K Yokoyama; Tsaiping Li; Mujun Zhao
Journal:  Biochem J       Date:  2006-02-01       Impact factor: 3.857

4.  Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases.

Authors:  Alfred Balasa; Grace Gathungu; Peter Kisfali; E O'Brian Smith; Judy H Cho; Bela Melegh; Richard Kellermayer
Journal:  Int J Colorectal Dis       Date:  2010-02-02       Impact factor: 2.571

5.  Association of MSH6 mutation with glioma susceptibility, drug resistance and progression.

Authors:  Chaoran Xie; Hansong Sheng; Nu Zhang; Shiting Li; Xiangyu Wei; Xuesheng Zheng
Journal:  Mol Clin Oncol       Date:  2016-05-20

Review 6.  Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities.

Authors:  Michael A Edelbrock; Saravanan Kaliyaperumal; Kandace J Williams
Journal:  Mutat Res       Date:  2013-02-04       Impact factor: 2.433

7.  A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.

Authors:  E Cecchin; M D'Andrea; S Lonardi; C Zanusso; N Pella; D Errante; E De Mattia; J Polesel; F Innocenti; G Toffoli
Journal:  Pharmacogenomics J       Date:  2012-08-07       Impact factor: 3.550

8.  Large-scale computational identification of regulatory SNPs with rSNP-MAPPER.

Authors:  Alberto Riva
Journal:  BMC Genomics       Date:  2012-06-18       Impact factor: 3.969

9.  CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding.

Authors:  Dong Li; Liang Da; Hong Tang; Tsaiping Li; Mujun Zhao
Journal:  Nucleic Acids Res       Date:  2007-11-22       Impact factor: 16.971

10.  WRN Germline Mutation Is the Likely Inherited Etiology of Various Cancer Types in One Iranian Family.

Authors:  Mahnaz Norouzi; Mohammad Shafiei; Zeinab Abdollahi; Paniz Miar; Hamid Galehdari; Mohammad Hasan Emami; Mehrdad Zeinalian; Mohammad Amin Tabatabaiefar
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.